242452-33-1

Basic information

• Product Name: 1-(N,N'-diBoc)-guanidinomethyl-4-aminomethylcyclohexane
• Synonyms: 1-(N,N'-diBoc)-guanidinomethyl-4-aminomethylcyclohexane
• CAS NO: 242452-33-1
• Molecular Weight: 384.519
• Mol File: 242452-33-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(N,N'-diBoc)-guanidinomethyl-4-aminomethylcyclohexane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(N,N'-diBoc)-guanidinomethyl-4-aminomethylcyclohexane(242452-33-1)
• EPA Substance Registry System: 1-(N,N'-diBoc)-guanidinomethyl-4-aminomethylcyclohexane(242452-33-1)

Safety Data

• Hazardous Substances Data: 242452-33-1(Hazardous Substances Data)

Upstream product

• 2549-93-1 1,4-bis-(aminomethyl)cyclohexane 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 

Downstream Products

• 263854-29-1 C₃₅H₅₈N₄O₄ 

Relevant articles and documents

The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists

A novel series of non-peptide derivatives 1, 14, and 15 that bind with high affinity to the human GnRH receptors is discussed. The discovery was made from screening our in-house libraries that contained the active structure 2 along with a trace amount of a second active structure 1 that was derived from an acid-induced rearrangement. From this structure type 1, a series of guanidine and non-guanidine containing analogues were prepared and tested as GnRH receptor antagonists. Compounds derived from this series bind to both human and rat GnRH receptors and antagonize GnRH-mediated increases in inositol phosphate production in cells containing recombinant human receptors. These compounds or their analogues may be useful as therapeutic agents for the treatment of hormone-dependent pathologies including prostate, breast and ovarian cancers.

Non-peptide GnRH agents, methods and intermediates for their preparation

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.